Australian medical cannabis company Bod Australia Limited (ASX: BDA) has entered into an agreement with Drug Science UK that includes a study of Bod’s MediCabilis product for the treatment of symptoms associated with long-term COVID.

“Long COVID” is a phenomenon in which symptoms persist for weeks or months beyond the original illness. Far from being isolated cases, it appears that long COVID is quite common; But as with the initial illness, the effects vary from patient to patient. Even asymptomatic people with relatively mild cases have reportedly suffered from prolonged COVID.

At the time of writing, there have been more than 122 million cases of COVID-19 worldwide. It is estimated that 10% of people who test positive will have symptoms 12 weeks after being diagnosed.

Commonly reported symptoms are lethargy, muscle pain, loss of smell and taste, and shortness of breath. For some, it can be debilitating and prevent them from engaging in normal levels of activity. In addition to the physical effects, there are also the psychological effects that can manifest as fear.


As the disease remains a mystery and more people experience it over time, there must be ways to deal with long COVID.

Bods MediCabilis is currently used for a number of conditions including pain and anxiety. The company believes it could help patients with long-term COVID illnesses. MediCabilis is a cannabidiol (CBD) based formulation in pharmaceutical quality in oil and wafer form.

Bod and Drug Science are developing a clinical study to investigate the effectiveness of prescribing MediCabilis for long-term COVID. The protocol for the study, which will take place in the UK, is currently being finalized through a collaboration between the two, and Bod expects it to begin in the coming months.

Bod will sponsor and provide Medicabilis for the study, while Drug Science will conduct the study according to good clinical practice standards through a licensed UK cannabis subscriber and will be responsible for collecting and analyzing all data.

In addition to medicinal cannabis products, Bod Australia is also involved in the development of non-medicinal health and skin care products based on hemp and other plants. Last year, the company partnered with vitamin and skin care giant Swisse Wellness to bring hemp products to the Australian market.